HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ERSP case

This article was originally published in The Rose Sheet

Executive Summary

1-800-Pharmacy has failed to respond to an inquiry by the Electronic Retailing Self-Regulation Program regarding core claims made in Web site advertising for OHT Peptide-3 Anti-Aging System, watchdog group says July 13. Claims at issue include "contains the exact, clinically tested dosage of each ingredient. This potency ensures that OHT Peptide-3 delivers efficacious results"; "results correspond to a restructuring of the tissue"; and "Experience OHT Peptide-3's Safe, Botox-like Effects," according to ERSP. 1-800-Pharmacy must submit substantiation for the core claims in 10 days, ERSP notes, adding failure to respond will result in referral of the case to the Federal Trade Commission...

You may also be interested in...

Skin Care Direct Response Marketer Referred To FTC By ERSP

The National Advertising Review Council's Electronic Retailing Self-Regulation Program is referring direct response company Boehm-Ritter to the Federal Trade Commission following the firm's failure to provide substantiation for Internet ad claims for its Nexiderm-SP Wrinkle-Reduction Cream

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 6)

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this sixth installment of a 10-part series, experts David Elder and John McKay address communication between the front room – where investigators do the majority of their work – and the back room, used by company workers to fulfill investigator requests for documents, records and other information.

Novartis MS Drug Mayzent Gets Europe OK

Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts